Owens & Minor Inc Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michael Roman Minchak - JPMorgan Chase & Co, Research Division - Analyst : Congratulations on the results. Maybe just following up on a couple of the previous questions as it relates to the debt paydown. So using the proceeds from the equity offering and what you've set aside from Movianto, leverage will be down substantially versus the beginning of the year. I was just wondering if you could talk about sort of your longer-term targets there in terms of leverage, when do you expect to get there, and then maybe discuss your priorities for capital allocation once you do get to that target leverage ratio.

Question: Michael Roman Minchak - JPMorgan Chase & Co, Research Division - Analyst : Got it. That's really helpful. Maybe just I'll wrap up with one more quick one here. With potential COVID-19 vaccines coming to market, I know the cold chain vaccine distribution is not really an area where Owens & Minor participates, but do you see any potential opportunity to benefit in other areas, whether it be incremental sales of ancillary products or PP&E?